Australia has the scientific and technical capability to develop and manufacture innovative diagnostic tests at the frontier of the world’s health needs.
More than 97 per cent of the in vitro diagnostic (IVD) tests and technologies used in Australia are imported and as a result, much of this technology is manufactured offshore, exposing Australia to supply shortages during periods of high demand and stress on global supply chains. While it is unrealistic for Australia to be fully self-sufficient in all aspects of health technologies and consumables, the COVID-19 pandemic has revealed an underlying need to develop and produce, reliably and sustainably, a critical few.
The Action Plan makes a range of practical recommendations to achieve the goal of a flourishing sovereign diagnostics manufacturing ecosystem and is the culmination of extensive consultation with more than 140 stakeholders across the country and direct contributions from those at the frontline.
The plan prepared with PTA and supported by HTANALYSTS capitalises on the local industry’s existing strengths, while prioritising innovation, boosting expertise and reducing investment risk.
It outlines a framework for enhancing the diagnostic infrastructure, supporting commercialisation of new innovations, improving access to testing, and strengthening the regulatory framework for diagnostic products and services.
Key recommendations from the report, Diagnostic Technology Sovereign Capability & Resilience: A National Action Plan, include:
